{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 437202892
| IUPAC_name = 2-(2-Hydroxybenzoyl)oxybenzoic acid
| image = Salsalate.svg
<!--Clinical data-->
| tradename = Disalcid, Salflex
| Drugs.com = {{drugs.com|monograph|salsalate}}
| MedlinePlus = a682880
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = Rx-only
| legal_status =
| routes_of_administration =
<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 552-94-3
| ATC_prefix = N02
| ATC_suffix = BA06
| PubChem = 5161
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01399
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 9014
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4977
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = V9MO595C9I
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D00428
<!--Chemical data-->
| C=14 | H=10 | O=5
| molecular_weight = 258.23 g/mol
}}

'''Salsalate''' is a medication that belongs to the [[salicylate]] and [[nonsteroidal anti-inflammatory drug]] (NSAID) classes. 

Salsalate is the generic name of a prescription drug marketed under the [[brandname]]s Mono-Gesic, Salflex, Disalcid, and Salsitab.  Other generic and brand name formulations may be available.<ref>[http://www.drugs.com/mtm/salsalate.html drugs.com Salsalate entry]</ref>

==Mechanism of action==
Relative to other NSAIDs, salsalate has a weak inhibitory effect on the [[cyclooxygenase]] enzyme and decreases the production of several proinflammatory [[cytokine|chemical signals]] such as [[interleukin-6]], [[TNF-alpha]], and [[C-reactive protein]].<ref name="Anderson2014" /> 

The mechanism through which salsalate is thought to reduce the production of these inflammatory chemical signals is through the inhibition of [[IκB kinase]] resulting in decreased action of [[NF-κB]] genes.<ref name="Anderson2014" /><ref name="Esser2015">{{cite journal|authors=Esser N, Paquot N, Scheen AJ|title=Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease|journal=Exp Opin Investig Drugs|date=March 2015|volume=24|issue=3|pages=283–307|pmid=25345753|doi=10.1517/13543784.2015.974804|type=Review}}</ref><ref name="Ridker2014">{{cite journal|authors=Ridker PM, Lüscher TF|title=Anti-inflammatory therapies for cardiovascular disease|journal=Eur Heart Journal|date=July 2014|volume=35|issue=27|pages=1782–91|pmid=24864079|pmc=4155455|doi=10.1093/eurheartj/ehu203}}</ref> This mechanism is thought to be responsible for salsalate's [[Insulin resistance|insulin-sensitizing]] and [[Blood glucose|blood sugar]] lowering properties.<ref name="Esser2015" />

== Medical uses ==
Salsalate may be used for inflammatory disorders such as [[rheumatoid arthritis]] or noninflammatory disorders such as [[osteoarthritis]].<ref name="Anderson2014" /><ref name="Hardie2013">{{cite journal|authors=Hardie DG|title=AMPK: a target for drugs and natural products with effects on both diabetes and cancer|journal=Diabetes|date=July 2013|volume=62|issue=7|pages=2164–72|pmid=23801715|pmc=3712072|doi=10.2337/db13-0368}}</ref>

== Safety ==
The risk of [[Hemorrhage|bleeding]] is a common concern with use of the NSAID class of medications. However, the bleeding risk associated with salsalate is lower than that associated with [[aspirin]] use.<ref name="Esser2015" />

== Research ==

Salsalate has been proposed for the prevention and treatment of [[type 2 diabetes]] mellitus due to its ability to lower [[insulin resistance]] associated with inflammation and may be useful in [[prediabetes]].<ref name="Anderson2014">{{cite journal|authors=Anderson K, Wherle L, Park M, Nelson K, Nguyen L|title=Salsalate, an old, inexpensive drug with potential new indications: a review of the evidence from 3 recent studies|journal=Am Health Drug Benefits|date=June 2014|volume=7|issue=4|pages=231–5|pmid=25126374|pmc=4105730}}</ref> However, the use of salsalate to prevent the progression from prediabetes to type 2 diabetes mellitus has received limited study.<ref name="Anderson2014" />

== History ==
Salsalate had been suggested as possible treatment for diabetes as early as 1876.<ref name="Anderson2014" /><ref name="nature2007">{{cite journal |url=|title=The Two Faces of Fat|first=Kendall|last=Powell|journal=Nature|volume=447|issue=7144|pages=525–7|date=May 31, 2007|pmid=17538594|doi=10.1038/447525a}}</ref><ref>{{cite journal |author=Ebstein, W |title= Zur therapie des diabetes mellitus, insbesondere uber die anwendung des salicylsauren natron bei demselben|journal=Berliner Klinische Wochenschrift|volume=13|pages=337–340|year=1876 }}</ref>

== Synthesis ==
[[File:Salsalatesynthesis.svg|center|thumb|750px|Salsalate synthesis:<ref>{{Cite journal|doi=10.1021/ja01251a034|title=Synthesis of Phenolic Acid Esters. I. Depsides1|journal=Journal of the American Chemical Society|volume=65|issue=11|pages=2140|year=1943|last1=Cavallito|first1=Chester J.|last2=Buck|first2=Johannes S.}}</ref><ref>{{Cite journal|doi=10.1039/JR9510000201|title=42. Eight- and higher-membered ring compounds. Part II. Di-, tri-, tetra-, and hexa-salicylides|journal=Journal of the Chemical Society (Resumed)|pages=201|year=1951|last1=Baker|first1=Wilson|last2=Ollis|first2=W. D.|last3=Zealley|first3=T. S.}}</ref> {{Cite patent|DE|211403}} and {{Cite patent|DE|214044}} (1909, both to Boehringer, Mann.), Frdl. 9, 928 and C.A. 4, 368 (1910).]]

== References ==
{{Reflist|30em}}

{{Anti-inflammatory and antirheumatic products}}
{{Salicylates}}
{{Prostanoidergics}}

[[Category:Nonsteroidal anti-inflammatory drugs]]
[[Category:Salicylates]]


{{analgesic-stub}}